Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas

Dusica Babovic-Vuksanovic, Brigitte C. Widemann, Eva Dombi, Andrea Gillespie, Pamela L. Wolters, Mary Anne Toledo-Tamula, Brian Patrick O'Neill, Elizabeth Fox, Tobey MacDonald, Heather Beck, Roger J. Packer

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We aimed to define the dose of pirfenidone in children and adolescents with neurofibromatosis 1 and plexiform neurofibromas that is pharmacokinetically comparable to the active adult dose. Pirfenidone was administered orally on a continuous dosing schedule. The starting dose level was 250 mg/m2/dose. The second dose level (500 mg/m2/dose) corresponded to the adult dose that previously showed activity in sclerosing conditions. A dose was considered pharmacokinetically comparable if the drug exposure in children was <1 standard deviation below the drug exposure in adults treated with 800 mg three times a day. Pharmacokinetic sampling was performed for 24 hours after the first dose. Response to treatment was evaluated using automated volumetric magnetic resonance imaging analysis; quality of life was evaluated using the Impact of Pediatric Illness Scale. Sixteen patients were entered and evaluated for toxicity. Dose-limiting toxicities were observed in 2 of 12 patients receiving 500 mg/m2 three times a day. The plasma pharmacokinetics of pirfenidone were highly variable, but not age dependent. The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma.

Original languageEnglish (US)
Pages (from-to)293-300
Number of pages8
JournalPediatric Neurology
Volume36
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Plexiform Neurofibroma
Neurofibromatosis 1
Pharmacokinetics
Pharmaceutical Preparations
Appointments and Schedules
Quality of Life
Magnetic Resonance Imaging
Pediatrics
pirfenidone

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Babovic-Vuksanovic, D., Widemann, B. C., Dombi, E., Gillespie, A., Wolters, P. L., Toledo-Tamula, M. A., ... Packer, R. J. (2007). Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas. Pediatric Neurology, 36(5), 293-300. https://doi.org/10.1016/j.pediatrneurol.2007.01.009

Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas. / Babovic-Vuksanovic, Dusica; Widemann, Brigitte C.; Dombi, Eva; Gillespie, Andrea; Wolters, Pamela L.; Toledo-Tamula, Mary Anne; O'Neill, Brian Patrick; Fox, Elizabeth; MacDonald, Tobey; Beck, Heather; Packer, Roger J.

In: Pediatric Neurology, Vol. 36, No. 5, 05.2007, p. 293-300.

Research output: Contribution to journalArticle

Babovic-Vuksanovic, D, Widemann, BC, Dombi, E, Gillespie, A, Wolters, PL, Toledo-Tamula, MA, O'Neill, BP, Fox, E, MacDonald, T, Beck, H & Packer, RJ 2007, 'Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas', Pediatric Neurology, vol. 36, no. 5, pp. 293-300. https://doi.org/10.1016/j.pediatrneurol.2007.01.009
Babovic-Vuksanovic, Dusica ; Widemann, Brigitte C. ; Dombi, Eva ; Gillespie, Andrea ; Wolters, Pamela L. ; Toledo-Tamula, Mary Anne ; O'Neill, Brian Patrick ; Fox, Elizabeth ; MacDonald, Tobey ; Beck, Heather ; Packer, Roger J. / Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas. In: Pediatric Neurology. 2007 ; Vol. 36, No. 5. pp. 293-300.
@article{886554b037714838a76340cdec59a9d1,
title = "Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas",
abstract = "We aimed to define the dose of pirfenidone in children and adolescents with neurofibromatosis 1 and plexiform neurofibromas that is pharmacokinetically comparable to the active adult dose. Pirfenidone was administered orally on a continuous dosing schedule. The starting dose level was 250 mg/m2/dose. The second dose level (500 mg/m2/dose) corresponded to the adult dose that previously showed activity in sclerosing conditions. A dose was considered pharmacokinetically comparable if the drug exposure in children was <1 standard deviation below the drug exposure in adults treated with 800 mg three times a day. Pharmacokinetic sampling was performed for 24 hours after the first dose. Response to treatment was evaluated using automated volumetric magnetic resonance imaging analysis; quality of life was evaluated using the Impact of Pediatric Illness Scale. Sixteen patients were entered and evaluated for toxicity. Dose-limiting toxicities were observed in 2 of 12 patients receiving 500 mg/m2 three times a day. The plasma pharmacokinetics of pirfenidone were highly variable, but not age dependent. The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma.",
author = "Dusica Babovic-Vuksanovic and Widemann, {Brigitte C.} and Eva Dombi and Andrea Gillespie and Wolters, {Pamela L.} and Toledo-Tamula, {Mary Anne} and O'Neill, {Brian Patrick} and Elizabeth Fox and Tobey MacDonald and Heather Beck and Packer, {Roger J.}",
year = "2007",
month = "5",
doi = "10.1016/j.pediatrneurol.2007.01.009",
language = "English (US)",
volume = "36",
pages = "293--300",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas

AU - Babovic-Vuksanovic, Dusica

AU - Widemann, Brigitte C.

AU - Dombi, Eva

AU - Gillespie, Andrea

AU - Wolters, Pamela L.

AU - Toledo-Tamula, Mary Anne

AU - O'Neill, Brian Patrick

AU - Fox, Elizabeth

AU - MacDonald, Tobey

AU - Beck, Heather

AU - Packer, Roger J.

PY - 2007/5

Y1 - 2007/5

N2 - We aimed to define the dose of pirfenidone in children and adolescents with neurofibromatosis 1 and plexiform neurofibromas that is pharmacokinetically comparable to the active adult dose. Pirfenidone was administered orally on a continuous dosing schedule. The starting dose level was 250 mg/m2/dose. The second dose level (500 mg/m2/dose) corresponded to the adult dose that previously showed activity in sclerosing conditions. A dose was considered pharmacokinetically comparable if the drug exposure in children was <1 standard deviation below the drug exposure in adults treated with 800 mg three times a day. Pharmacokinetic sampling was performed for 24 hours after the first dose. Response to treatment was evaluated using automated volumetric magnetic resonance imaging analysis; quality of life was evaluated using the Impact of Pediatric Illness Scale. Sixteen patients were entered and evaluated for toxicity. Dose-limiting toxicities were observed in 2 of 12 patients receiving 500 mg/m2 three times a day. The plasma pharmacokinetics of pirfenidone were highly variable, but not age dependent. The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma.

AB - We aimed to define the dose of pirfenidone in children and adolescents with neurofibromatosis 1 and plexiform neurofibromas that is pharmacokinetically comparable to the active adult dose. Pirfenidone was administered orally on a continuous dosing schedule. The starting dose level was 250 mg/m2/dose. The second dose level (500 mg/m2/dose) corresponded to the adult dose that previously showed activity in sclerosing conditions. A dose was considered pharmacokinetically comparable if the drug exposure in children was <1 standard deviation below the drug exposure in adults treated with 800 mg three times a day. Pharmacokinetic sampling was performed for 24 hours after the first dose. Response to treatment was evaluated using automated volumetric magnetic resonance imaging analysis; quality of life was evaluated using the Impact of Pediatric Illness Scale. Sixteen patients were entered and evaluated for toxicity. Dose-limiting toxicities were observed in 2 of 12 patients receiving 500 mg/m2 three times a day. The plasma pharmacokinetics of pirfenidone were highly variable, but not age dependent. The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma.

UR - http://www.scopus.com/inward/record.url?scp=34248177910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248177910&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2007.01.009

DO - 10.1016/j.pediatrneurol.2007.01.009

M3 - Article

C2 - 17509460

AN - SCOPUS:34248177910

VL - 36

SP - 293

EP - 300

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 5

ER -